Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment

Biomaterials

Volumn 35, Issue 10, 2014, Pages 3365-3383

  Naksuriya, Ornchuma ^a,b   Okonogi, Siriporn ^a   Schiffelers, Raymond M ^c   Hennink, Wim E ^b  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cancer; Clinical studies; Curcumin; Drug delivery; Nanoformulation; Nanomedicine

Indexed keywords

CANCER; CLINICAL STUDY; CURCUMIN; DESIGN AND DEVELOPMENT; MYOCARDIAL INFARCTION; NANOFORMULATION; PHARMACOLOGICAL ACTIVITY; POLYMERIC NANOPARTICLES;

CELL CULTURE; DRUG DELIVERY; LIPOSOMES; MEDICAL APPLICATIONS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

DISEASES;

CURCUMIN; CYCLODEXTRIN; DRUG CARRIER; LIPID EMULSION; LIPOSOME; NANOPARTICLE; PEPTIDE;

CANCER CHEMOTHERAPY; CONJUGATE; DISPERSION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICELLE; NEOPLASM; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SOLID; TUMOR CELL LINE;

CURCUMA LONGA;

CANCER; CLINICAL STUDIES; CURCUMIN; DRUG DELIVERY; NANOFORMULATION; NANOMEDICINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHEMISTRY, PHARMACEUTICAL; CURCUMIN; DRUG CARRIERS; MICELLES; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 84893694889     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.090     Document Type: Review

References (212)

1. Vogel H.A., Pelletier J. Curcumin-biological and medicinal properties. J Pharmacol 1815, 2. 50-50.
2. Milobedeska J., Kostanecki V., Lampe V. Structure of curcumin. Ber Dtsch Chem Ges 1910, 43:2163-2170.
3. Lampe V., Milobedeska J. Studien über curcumin. Ber Dtsch Chem Ges 1913, 46:2235-2240.
4. Sandur S.K., Pandey M.K., Sung B., Ahn K.S., Murakami A., Sethi G., et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007, 28:1765-1773.
5. Liu Y., Hong X. Effect of three different curcumin pigments on the proliferation of vascular smooth muscle cells by ox-LDL and the expression of LDL-R. Zhongguo Zhong Yao Za Zhi 2006, 31:500-503.
6. Kim D.S.H.L., Park S.Y., Kim J.Y. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA (1-42) insult. Neurosci Lett 2001, 303:57-61.
7. Nishiyama T., Mae T., Kishida H., Tsukagawa M., Mimaki Y., Kuroda M., et al. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem 2005, 53:959-963.
8. Kiuchi F., Goto Y., Sugimoto N., Akao N., Kondo K., Tsuda Y. Nematocidal activity of turmeric: synergistic action of curcuminoids. Chem Pharm Bull 1993, 41:1640-1643.
9. Sharma R., Gescher A., Steward W. Curcumin: the story so far. Eur J Cancer 2005, 41:1955-1968.
10. Asai A., Miyazawa T. Dietary curcuminoids prevent high-fat diet-induced lipid accumulation in rat liver and epididymal adipose tissue. J Nutr 2001, 131:2932-2935.
11. Aggarwal B.B. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 2010, 30:173-199.
12. Olszanecki R., Jawień J., Gajda M., Mateuszuk L., Gebska A., Korabiowska M., et al. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2005, 56:627-635.
13. Shin S.K., Ha T.Y., McGregor R.A., Choi M.S. Longterm curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 2011, 55:1829-1840.
14. 2+ signaling. Biochem Pharmacol 1999, 58:1167-1172.
15. Aggarwal B.B., Kumar A., Bharti A.C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003, 23:363-398.
16. Jagetia G.C., Aggarwal B.B. "Spicing up" of the immune system by curcumin. J Clin Immunol 2007, 27:19-35.
17. Aggarwal B.B., Sundaram C., Malani N., Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2006, 595:1-75.
18. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as ''curecumin'': from kitchen to clinic. Biochem Pharmacol 2008, 75:787-809.
19. Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 2009, 41:40-59.
20. Duvoix A., Blasius R., Delhalle S., Schnekenburger M., Morceau F., Henry E., et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 2005, 223:181-190.
21. Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B., Aggarwal B.B. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008, 267:133-164.
22. Bar-Sela G., Epelbaum R., Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010, 17:190-197.
23. Ravindran J., Prasad S., Aggarwal B.B. Curcumin and cancer cells: how many ways can curry kill tumor cells selectivelyα. AAPS J 2009, 11:495-510.
24. Maheshwari R.K., Singh A.K., Gaddipati J., Srimal R.C. Multiple biological activities of curcumin: a short review. Life Sci 2006, 78:2081-2087.
25. Shishodia S., Chaturvedi M.M. Role of curcumin in cancer therapy. Curr Prob Cancer 2007, 31:243-305.
26. Aggarwal B.B., Ichikawa H., Garodia P., Weerasinghe P., Sethi G., Bhatt I.D., et al. From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin Ther Targets 2006, 10:87-118.
27. Kamat A.M., Sethi G., Aggarwal B.B. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in IFN-α-sensitive and IFN-α-resistant human bladder cancer cells. Mol Cancer Ther 2007, 6:1022-1030.
28. Cheng A., Hsu C., Lin J., Hsu M., Ho Y., Shen T., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
29. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., et al. Phase I clinical trial of oral curcumin biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10:6847-6854.
30. Hatcher H., Planalp R., Cho J., Torti F., Torti S. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008, 65:1631-1652.
31. Balaji S., Chempakam B. Toxicity prediction of compounds from turmeric (Curcuma longa L). Food Chem Toxicol 2010, 48:2951-2959.
32. Fujisawa S., Atsumi T., Ishihara M., Kadoma Y. Cytotoxicity, ROS-generation activity and radical-scavenging activity of curcumin and related compounds. Anticancer Res 2004, 24:563-570.
33. Kurien B.T., Singh A., Matsumoto H., Scofield R.H. Improving the solubility and pharmacological efficacy of curcumin by heat treatment. Assay Drug Dev Techn 2007, 5:567-576.
34. Tønnesen H.H., Másson M., Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability. Int J Pharm 2002, 244:127-135.
35. Wang Y.J., Pan M.H., Cheng A.L., Lin L.I., Ho Y.S., Hsieh C.Y., et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed 1997, 15:1867-1876.
36. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharmcol 2007, 4:807-818.
37. Yang K., Lin L., Tseng T., Wang S., Tsai T. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J Chromatogr B 2007, 853:183-189.
38. Shoba G., Joy D., Joseph T., Majeed M., Rajendran R., Srinivas P. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 2007, 64:353-356.
39. Torchilin V. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009, 7:431-444.
40. Ruenraroengsak P., Cook J.M., Florence A.T. Nanosystem drug targeting: facing up to complex realities. J Control Release 2010, 141:265-276.
41. Sultana S., Khan M.R., Kumar M., Kumar S., Ali M. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review. J Drug Target 2013, 21:107-125.
42. Lammers T., Aime S., Hennink W.E., Storm G., Kiessling F. Theranostic nanomedicine. Accounts Chem Res 2011, 44:1029-1038.
43. Duncan R., Richardson S.C. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. Mol Pharm 2012, 9:2380-2402.
44. Devadasu V., Bhardwaj V., Kumar M. Can controversial nanotechnology promise drug deliveryα. Chem Rev 2013, 113:1686-1735.
45. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
46. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
47. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
48. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63:131-135.
49. Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:1-11.
50. Svenson S. Clinical translation of nanomedicines. Curr Opin Solid St M 2012, 16:287-294.
51. Tong R., Gabrielson N.P., Fan T.M., Cheng J. Polymeric nanomedicines based on poly(lactide) and poly(lactide-co-glycolide). Curr Opin Solid St M 2012, 16:323-332.
52. Duncan R., Gaspar R. Nanomedicine (s) under the microscope. Mol Pharm 2011, 8:2101-2141.
53. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005, 4:145-160.
54. Torchilin V.P. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009, 71:431-444.
55. Barenholz Y. Doxil-the first FDA-approved nano-drug: lessons learned. J Control Release 2012, 160:117-134.
56. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30:592-599.
57. Karewicz A., Bielska D., Gzyl-Malcher B., Kepczynski M., Lach R., Nowakowska M. Interaction of curcumin with lipid monolayers and liposomal bilayers. Colloid Surf B 2011, 88:231-239.
58. Karewicz A., Bielska D., Loboda A., Gzyl-Malcher B., Bednar J., Jozkowicz A. Curcumin-containing liposomes stabilized by thin layers of chitosan derivatives. Colloid Surf B 2013, 109:307-316.
59. Re F., Cambianica I., Zona C., Sesana S., Gregori M., Rigolio R. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomed Nanotechnol 2011, 7:551-559.
60. Lin Y.L., Liu Y.K., Tsai N.M., Hsieh J.H., Chen C.H., Lin C.M., et al. A lipo-PEG-PEI complex for encapsulating curcumin that enhances its antitumor effects on curcumin-sensitive and curcumin-resistance cells. Nanomed Nanotechnol 2012, 8:318-327.
61. Li C., Zhang Y., Su T., Feng L., Long Y., Chen Z. Silica-coated flexible liposomes as a nanohybrid delivery system for enhanced oral bioavailability of curcumin. Int J Nanomed 2011, 7:5995-6002.
62. Lazar A., Mourtas S., Youssef I., Parizot C., Dauphin A., Delatour B., et al. Curcumin-conjugated nanoliposomes with high affinity for Aβ deposits: possible applications to Alzheimer disease. Nanomed-Nanotechnol 2013, 9:712-721.
63. Aditya N., Chimote G., Gunalan K., Banerjee R., Patankar S., Madhusudhan B. Curcuminoids-loaded liposomes in combination with arteether protects against Plasmodium berghei infection in mice. Exp Parasitol 2012, 131:292-299.
64. Rogers N.M., Stephenson M.D., Kitching A., Horowitz J.D., Coates P.T.H. Amelioration of renal ischaemia-reperfusion injury by liposomal delivery of curcumin to renal tubular epithelial and antigen-presenting cells. Br J Pharmacol 2012, 166:194-209.
65. Sun M., Su X., Ding B., He X., Liu X., Yu A., et al. Advances in nanotechnology-based delivery systems for curcumin. Nanomedicine UK 2012, 7:1085-1100.
66. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012, 161:505-522.
67. Fredenberg S., Wahlgren M., Reslow M., Axelsson A. The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems-a review. Int J Pharm 2011, 415:34-52.
68. Chaisri W., Ghassemi A.H., Hennink W.E., Okonogi S. Enhanced gentamicin loading and release of PLGA and PLHMGA microspheres by varying the formulation parameters. Colloids Surf B 2011, 84:508-514.
69. Jain R.A. The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide)(PLGA) devices. Biomaterials 2000, 21:2475-2490.
70. Acharya S., Sahoo S.K. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 2011, 63:170-183.
71. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24.
72. Ford Versypt A.N., Pack D.W., Braatz R.D. Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres-a review. J Control Release 2013, 165:29-37.
73. Shaikh J., Ankola D., Beniwal V., Singh D., Kumar M. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009, 37:223-230.
74. Yallapu M.M., Gupta B.K., Jaggi M., Chauhan S.C. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 2010, 351:19-29.
75. Doane T.L., Chuang C.H., Hill R.J., Burda C. Nanoparticle ζ-potentials. Accounts Chem Res 2012, 45:317-326.
76. Ghosh D., Choudhury S.T., Ghosh S., Mandal A.K., Sarkar S., Ghosh A., et al. Nanocapsulated curcumin: oral chemopreventive formulation against diethylnitrosamine induced hepatocellular carcinoma in rat. Chem Biol Interact 2012, 195:206-214.
77. Anand P., Nair H.B., Sung B., Kunnumakkara A.B., Yadav V.R., Tekmal R.R., et al. Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 2010, 79:330-338.
78. Khalil N.M., do Nascimento T.C.F., Casa D.M., Dalmolin L.F., de Mattos A.C., Hoss I., et al. Pharmacokinetics of curcumin-loaded PLGA and PLGA-PEG blend nanoparticles after oral administration in rats. Colloid Surf B 2013, 101:353-360.
79. Bisht S., Feldmann G., Soni S., Ravi R., Karikar C., Maitra A., et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology 2007, 5:1-18.
80. Liu J., Xu L., Liu C., Zhang D., Wang S., Deng Z., et al. Preparation and characterization of cationic curcumin nanoparticles for improvement of cellular uptake. Carbohyd Polym 2012, 90:16-22.
81. Rejinold N., Sreerekha P., Chennazhi K., Nair S., Jayakumar R. Biocompatible, biodegradable and thermo-sensitive chitosan-g-poly (N-isopropylacrylamide) nanocarrier for curcumin drug delivery. Int J Biol Macromol 2011, 49:161-172.
82. Dimitrov I., Trzebicka B., Müller A.H., Dworak A., Tsvetanov C.B. Thermosensitive water-soluble copolymers with doubly responsive reversibly interacting entities. Prog Polym Sci 2007, 32:1275-1343.
83. Schmaljohann D. Thermo-and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev 2006, 58:1655-1670.
84. Anitha A., Deepagan V., Divya rani V., Menon D., Nair S., Jayakumar R. Preparation, characterization, in vitro drug release and biological studies of curcumin loaded dextran sulphate-chitosan nanoparticles. Carbohyd Polym 2011, 84:1158-1164.
85. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001, 47:113-131.
86. Gaucher G., Dufresne M.H., Sant V.P., Kang N., Maysinger D., Leroux J.C. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005, 109:169-188.
87. Gaucher G., Satturwar P., Jones M.C., Furtos A., Leroux J.C. Polymeric micelles for oral drug delivery. Eur J Pharm Biopharm 2010, 76:147-158.
88. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J.F.W., Hennink W.E. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010, 27:2569-2589.
89. Talelli M., Rijcken C.J., Hennink W.E., Lammers T. Polymeric micelles for cancer therapy: 3 C's to enhance efficacy. Curr Opin Solid St M 2012, 16:302-309.
90. Matsumura Y., Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009, 100:572-579.
91. Deng C., Jiang Y., Cheng R., Meng F., Zhong Z. Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects. Nano Today 2012, 7:467-480.
92. Lu Y., Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm 2013, 453:198-214.
93. Song L., Shen Y., Hou J., Lei L., Guo S., Qian C. Polymeric micelles for parenteral delivery of curcumin: preparation, characterization and in vitro evaluation. Colloid Surf A 2011, 390:25-32.
94. Song Z., Feng R., Sun M., Guo C., Gao Y., Li L., et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011, 354:116-123.
95. Zhao L., Du J., Duan Y., Zang Y., Zhang H., Yang C., et al. Curcumin loaded mixed micelles composed of pluronic P123 and F68: preparation, optimization and in vitro characterization. Colloid Surf B 2012, 97:101-108.
96. Samanta S., Roccatano D. Interaction of curcumin with PEO-PPO-PEO triblock copolymers: a molecular dynamics study. J Phys Chem B 2013, 117:3250-3257.
97. Gong C., Deng S., Wu Q., Xiang M., Wei X., Li L., et al. Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials 2013, 34:1413-1432.
98. Ma Z., Haddadi A., Molavi O., Lavasanifar A., Lai R., Samuel J. Micelles of poly(ethylene oxide)-b-poly(E{open}-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res A 2008, 86:300-310.
99. Parvathy K., Negi P., Srinivas P. Curcumin-amino acid conjugates: synthesis, antioxidant and antimutagenic attributes. Food Chem 2010, 120:523-530.
100. Manju S., Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci 2011, 359:318-325.
101. Tang H., Murphy C.J., Zhang B., Shen Y., Sui M., Van Kirk E.A., et al. Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine 2010, 5:855-865.
102. Yang R., Zhang S., Kong D., Gao X., Zhao Y., Wang Z. Biodegradable polymer-curcumin conjugate micelles enhance the loading and delivery of low-potency curcumin. Pharm Res 2012, 29:3512-3525.
103. Wichitnithad W., Nimmannit U., Callery P.S., Rojsitthisak P. Effects of different carboxylic ester spacers on chemical stability, release characteristics, and anticancer activity of mono-PEGylated curcumin conjugates. J Pharm Sci 2011, 100:5206-5218.
104. Esmaili M., Ghaffari S.M., Moosavi-Movahedi Z., Atri M.S., Sharifizadeh A., Farhadi M., et al. Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin; food industry application. LWT Food Sci Technol 2011, 44:2166-2172.
105. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.
106. Elzoghby A.O., Samy W.M., Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 2012, 157:168-182.
107. Kim T.H., Jiang H.H., Youn Y.S., Park C.W., Tak K.K., Lee S., et al. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity. Int J Pharm 2011, 403:285-291.
108. Kragh-Hansen U., Hellec F., de Foresta B., le Maire M., Møller J.V. Detergents as probes of hydrophobic binding cavities in serum albumin and other water-soluble proteins. Biophys J 2001, 80:2898-2911.
109. Leung M.H., Kee T.W. Effective stabilization of curcumin by association to plasma proteins: human serum albumin and fibrinogen. Langmuir 2009, 25:5773-5777.
110. Loftsson T., Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007, 329:1-11.
111. Loftsson T., Magnúsdóttir A., Másson M., Sigurjónsdóttir J.F. Self-association and cyclodextrin solubilization of drugs. J Pharm Sci 2002, 91:2307-2316.
112. Yadav V.R., Prasad S., Kannappan R., Ravindran J., Chaturvedi M.M., Vaahtera L., et al. Cyclodextrin-complexed curcumin exhibits anti-inflammatory and antiproliferative activities superior to those of curcumin through higher cellular uptake. Biochem Pharmacol 2010, 80:1021-1032.
113. Yallapu M.M., Jaggi M., Chauhan S.C. β-Cyclodextrin-curcumin self-assembly enhances curcumin delivery in prostate cancer cells. Colloid Surf B 2010, 79:113-125.
114. Yallapu M.M., Jaggi M., Chauhan S.C. Poly (β-cyclodextrin)/curcumin self-assembly: a novel approach to improve curcumin delivery and its therapeutic efficacy in prostate cancer cells. Macromol Biosci 2010, 10:1141-1151.
115. Ford J.L. The current status of solid dispersions. Pharm Acta Helv 1986, 61:69-88.
116. Alam M.A., Ali R., Al-Jenoobi F.I., Al-Mohizea A.M. Solid dispersions: a strategy for poorly aqueous soluble drugs and technology updates. Expert Opin Drug Del 2012, 9:1419-1440.
117. Okonogi S., Oguchi T., Yonemochi E., Puttipipatkhachorn S., Yamamoto K. Physicochemical properties of ursodeoxycholic acid dispersed in controlled pore glass. J Colloid Interface Sci 1999, 216:276-284.
118. Okonogi S., Puttipipatkhachorn S. Dissolution improvement of high drug-loaded solid dispersion. AAPS Pharmscitech 2006, 7:148-153.
119. Janssens S., Van den Mooter G. Review: physical chemistry of solid dispersions. J Pharm Pharmacol 2009, 61:1571-1586.
120. Giri T.K., Kumar K., Alexander A., Ajazuddin, Badwaik H., Tripathi D.K. A novel and alternative approach to controlled release drug delivery system based on solid dispersion technique. B-FOPCU 2012, 50:147-159.
121. Hegge A., Vukicevic M., Bruzell E., Kristensen S., Tønnesen H. Solid dispersions for preparation of phototoxic supersaturated solutions for antimicrobial photodynamic therapy (aPDT): studies on curcumin and curcuminoides L. Eur J Pharm Biopharm 2013, 83:95-105.
122. ®HS15 as a carrier. Int J Pharm 2012, 424:18-25.
123. Mohanty C., Sahoo S.K. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010, 31:6597-6611.
124. Anuchapreeda S., Fukumori Y., Okonogi S., Ichikawa H. Preparation of lipid nanoemulsions incorporating curcumin for cancer therapy. J Nanotechnol 2012, 41:1-11.
125. Zanotto-Filho A., Coradini K., Braganhol E., Schröder R., de Oliveira C.M., Simões-Pires A., et al. Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioma treatment. Eur J Pharm Biopharm 2013, 83:156-167.
126. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J Control Release 2010, 145:182-195.
127. Nichols J.W., Bae Y.H. Odyssey of a cancer nanoparticle: from injection site to site of action. Nano Today 2012, 7:606-618.
128. Dhule S.S., Penfornis P., Frazier T., Walker R., Feldman J., Tan G., et al. Curcumin-loaded γ-cyclodextrin liposomal nanoparticles as delivery vehicles for osteosarcoma. Nanomed Nanotechnol 2012, 8:440-451.
129. Daleke D.L., Hong K., Papahadjopoulos D. Endocytosis of liposomes by macrophages: binding, acidification and leakage of liposomes monitored by a new fluorescence assay. BBA Biomembranes 1990, 1024:352-366.
130. Raveendran R., Bhuvaneshwar G., Sharma C.P. In vitro cytotoxicity and cellular uptake of curcumin-loaded pluronic/polycaprolactone micelles in colorectal adenocarcinoma cells. J Biomater Appl 2013, 27:811-827.
131. Park J.H., Kim H.A., Park J.H., Lee M. Amphiphilic peptide carrier for the combined delivery of curcumin and plasmid DNA into the lungs. Biomaterials 2012, 33:6542-6550.
132. Yallapu M.M., Ebeling M.C., Jaggi M., Chauhan S.C. Plasma proteins interaction with curcumin nanoparticles: implications in cancer therapeutics. Curr Drug Metab 2013, 14:504-515.
133. Zhang J., Zhang T., Ti X., Shi J., Wu C., Ren X., et al. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem Biophys Res Commun 2010, 399:1-6.
134. Duan J., Mansour H.M., Zhang Y., Deng X., Chen Y., Wang J., et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly (butyl cyanoacrylate) nanoparticles. Int J Pharm 2012, 426:193-201.
135. Zhongfa L., Chiu M., Wang J., Chen W., Yen W., Fan-Havard P., et al. Enhancement of curcumin oral absorption and pharmacokinetics of curcuminoids and curcumin metabolites in mice. Cancer Chemother Pharmacol 2012, 69:679-689.
136. Tobio M., Sanchez A., Vila A., Soriano I., Evora C., Vila-Jato J., et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloid Surf B 2000, 18:315-323.
137. Plapied L., Duhem N., des Rieux A., Préat V. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid 2011, 16:228-237.
138. Ghahremankhani A.A., Dorkoosh F., Dinarvand R. PLGA-PEG-PLGA tri-block copolymers as in situ gel-forming peptide delivery system: effect of formulation properties on peptide release. Pharm Dev Technol 2008, 13:49-55.
139. Thorne R.G., Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci U S A 2006, 103:5567-5572.
140. Serrano A.G., Pérez-Gil J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem Phys Lipids 2006, 141:105-118.
141. Gao Y., Li Z., Sun M., Li H., Guo C., Cui J., et al. Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer. Drug Dev Ind Pharm 2010, 36:1225-1234.
142. Zou P., Helson L., Maitra A., Stern S.T., McNeil S.E. Polymeric curcumin nanoparticle pharmacokinetics and metabolism in bile duct cannulated rats. Mol Pharm 2013, 10:1977-1987.
143. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008, 5:505-515.
144. Torchilin V.P., Trubetskoy V.S. Which polymers can make nanoparticulate drug carriers long-circulatingα. Adv Drug Deliv Rev 1995, 16:141-155.
145. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007, 9:128-147.
146. Woodle M.C. Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation. Chem Phys Lipids 1993, 64:249-262.
147. Li S.D., Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 2010, 145:178-181.
148. Romberg B., Hennink W.E., Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm Res 2008, 25:55-71.
149. Khandare J., Calderón M., Dagia N.M., Haag R. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. Chem Soc Rev 2012, 41:2824-2848.
150. Babaei E., Sadeghizadeh M., Hassan Z.M., Feizi M.A.H., Najafi F., Hashemi S.M. Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo. Int Immunopharmacol 2012, 12:226-234.
151. Murphy C., Tang H., Van Kirk E., Shen Y., Murdoch W. Reproductive effects of a pegylated curcumin. Reprod Toxicol 2012, 34:120-124.
152. Cheng K.K., Yeung C.F., Ho S.W., Chow S.F., Chow A.H., Baum L. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 Mice. AAPS J 2012, 15:324-336.
153. Cutrin J.C., Geninatti Crich S., Burghelea D., Dastrù W., Aime S. Curcumin/Gd loaded apoferritin: a novel "theranostic" agent to prevent hepatocellular damage in toxic induced acute hepatitis. Mol Pharm 2013, 10:2079-2085.
154. Li X., Nan K., Li L., Zhang Z., Chen H. In vivo evaluation of curcumin nanoformulation loaded methoxy poly (ethylene glycol)-graft-chitosan composite film for wound healing application. Carbohyd Polym 2012, 88:84-90.
155. Gong C., Wu Q., Wang Y., Zhang D., Luo F., Zhao X., et al. A biodegradable hydrogel system containing curcumin encapsulated in micelles for cutaneous wound healing. Biomaterials 2013, 34:6377-6387.
156. Chereddy K.K., Coco R., Memvanga P.B., Ucakar B., Rieux Ad, Vandermeulen G., et al. Combined effect of PLGA and curcumin on wound healing activity. J Control Release 2013, 171:208-215.
157. Kakkar V., Muppu S.K., Chopra K., Kaur I.P. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm 2013, 85:339-345.
158. Wang W., Zhu R., Xie Q., Li A., Xiao Y., Li K., et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomed 2012, 7:3667-3677.
159. Akhtar F., Rizvi M., Kar S.K. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv 2012, 30:310-320.
160. Sunagawa Y., Wada H., Suzuki H., Sasaki H., Imaizumi A., Fukuda H., et al. A novel drug delivery system of oral curcumin markedly improves efficacy of treatment for heart failure after myocardial infarction in rats. Biol Pharm Bull 2012, 35:139-144.
161. Gupta S.C., Patchva S., Aggarwal B.B. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013, 15:195-218.
162. Carroll R.E., Benya R.V., Turgeon D.K., Vareed S., Neuman M., Rodriguez L., et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res 2011, 4:354-364.
163. He Z.Y., Shi C.B., Wen H., Li F.L., Wang B.L., Wang J. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest 2011, 29:208-213.
164. Kanai M., Yoshimura K., Asada M., Imaizumi A., Suzuki C., Matsumoto S., et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011, 68:157-164.
165. Epelbaum R., Schaffer M., Vizel B., Badmaev V., Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010, 62:1137-1141.
166. Bayet-Robert M., Kwiatowski F., Leheurteur M., Gachon F., Planchat E., Abrial C., et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2010, 9:8-14.
167. Golombick T., Diamond T.H., Badmaev V., Manoharan A., Ramakrishna R. The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker. Clin Cancer Res 2009, 15:5917-5922.
168. Lao C.D., Ruffin M.T., Normolle D., Heath D.D., Murray S.I., Bailey J.M., et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 2006, 6:6-10.
169. Vareed S.K., Kakarala M., Ruffin M.T., Crowell J.A., Normolle D.P., Djuric Z., et al. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidem Biomar 2008, 17:1411-1417.
170. Garcea G., Berry D.P., Jones D.J., Singh R., Dennison A.R., Farmer P.B., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidem Biomar 2005, 14:120-125.
171. Gota V.S., Maru G.B., Soni T.G., Gandhi T.R., Kochar N., Agarwal M.G. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 2010, 58:2095-2099.
172. Sasaki H., Sunagawa Y., Takahashi K., Imaizumi A., Fukuda H., Hashimoto T. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 2011, 34:660-665.
173. Kanai M., Imaizumi A., Otsuka Y., Sasaki H., Hashiguchi M., Tsujiko K. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharm 2012, 69:65-70.
174. Kooijmans S.A., Vader P., van Dommelen S.M., van Solinge W.W., Schiffelers R.M. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomed 2012, 7:1525-1541.
175. Van Dommelen S.M., Vader P., Lakhal S., Kooijmans S., Van Solinge W.W., Wood M.J., et al. Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release 2012, 161:635-644.
176. Sun D., Zhuang X., Xiang X., Liu Y., Zhang S., Liu C., et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010, 18:1606-1614.
177. Shimatsu A., Kakeya H., Imaizumi A., Morimoto T., Kanai M., Maeda S. Clinical application of "curcumin", a multi-functional substance. J Anti-Aging Med 2012, 9:75-83.
178. Khar A., Ali A.M., Pardhasaradhi B., Varalakshmi C., Anjum R., Kumari A.L. Induction of stress response renders human tumor cell lines resistant to curcumin-mediated apoptosis: role of reactive oxygen intermediates. Cell Stress Chaperones 2001, 6:368-376.
179. Elattar T., Virji A. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Res 2000, 20:1733-1738.
180. Liebmann J., Cook J., Lipschultz C., Teague D., Fisher J., Mitchell J. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 1993, 68:1104-1109.
181. Limtrakul P., Chearwae W., Shukla S., Phisalphong C., Ambudkar S.V. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 2007, 296:85-95.
182. Chearwae W., Wu C.P., Chu H.Y., Lee T.R., Ambudkar S.V., Limtrakul P. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharm 2006, 57:376-388.
183. Zhang K.Z., Xu J.H., Huang X.W., Wu L.X., Su Y., Chen Y.Z. Curcumin synergistically augments bcr/abl phosphorothioate antisense oligonucleotides to inhibit growth of chronic myelogenous leukemia cells. Acta Pharmacol Sin 2007, 28:105-110.
184. El-Sayed E.M., El-azeem A.S.A., Afify A.A., Shabana M.H., Ahmed H.H. Cardioprotective effects of Curcuma longa L. extracts against doxorubicin-induced cardiotoxicity in rats. J Med Plants Res 2011, 5:4049-4058.
185. Bava S., Puliappadamba V., Deepti A., Nair A., Karunagaran D., Anto R. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 2005, 280:6301-6308.
186. Notarbartolo M., Poma P., Perri D., Dusonchet L., Cervello M., D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005, 224:53-65.
187. Kunnumakkara A.B., Guha S., Krishnan S., Diagaradjane P., Gelovani J., Aggarwal B.B. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κb-regulated gene products. Cancer Res 2007, 67:3853-3861.
188. Lin Y.G., Kunnumakkara A.B., Nair A., Merritt W.M., Han L.Y., Armaiz-Pena G.N. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin Cancer Res 2007, 13:3423-3430.
189. Ganta S., Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009, 6:928-939.
190. Misra R., Sahoo S.K. Coformulation of doxorubicin and curcumin in poly (D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 2011, 8:852-866.
191. Boztas A.O., Karakuzu O., Galante G., Ugur Z., Kocabas F., Altuntas C.Z., et al. Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. Mol Pharm 2013, 10:2676-2683.
192. López-Lázaro M. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. Mol Nutr Food Res 2008, 52:S103-S127.
193. Wang H., Mao Y., Chen A.Y., Zhou N., LaVoie E.J., Liu L.F. Stimulation of topoisomerase II-mediated DNA damage via a mechanism involving protein thiolation. Biochemistry 2001, 40:3316-3323.
194. Moos P.J., Edes K., Mullally J.E., Fitzpatrick F.A. Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 2004, 25:1611-1617.
195. Utkhede D.R., Tilcock C.P. Effect of lipid dose on the redistribution and blood pool clearance kinetics of peg-modified technetium-labeled lipid vesicles. J Liposome Res 1998, 8:381-390.
196. Koide H., Asai T., Hatanaka K., Urakami T., Ishii T., Kenjo E., et al. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm 2008, 362:197-200.
197. Lu W., Wan J., She Z., Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release 2007, 118:38-53.
198. Ishihara T., Takeda M., Sakamoto H., Kimoto A., Kobayashi C., Takasaki N., et al. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res 2009, 26:2270-2279.
199. Schellekens H., Hennink W.E., Brinks V. The immunogenicity of polyethylene glycol: facts and fiction. Pharm Res 2013, 30:1729-1734.
200. Ishida T., Wang X., Shimizu T., Nawata K., Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release 2007, 122:349-355.
201. Ishida T., Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 2008, 354:56-62.
202. Romberg B., Oussoren C., Snel C.J., Carstens M.G., Hennink W.E., Storm G. Pharmacokinetics of poly (hydroxyethyl-L-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. BBA-Biomembranes 2007, 1768:737-743.
203. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006, 1:297-315.
204. Shiraishi K., Hamano M., Ma H., Kawano K., Maitani Y., Aoshi T., et al. Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon. J Control Release 2013, 165:183-190.
205. Abu Lila A.S., Kiwada H., Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release 2013, 172:38-47.
206. Sou K., Inenaga S., Takeoka S., Tsuchida E. Loading of curcumin into macrophages using lipid-based nanoparticles. Int J Pharm 2008, 352:287-293.
207. Sou K., Goins B., Takeoka S., Tsuchida E., Phillips W. Selective uptake of surface-modified phospholipid vesicles by bone marrow macrophages in vivo. Biomaterials 2007, 28:2655-2666.
208. Ahsan F., Rivas I.P., Khan M.A., Torres Suárez A.I. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 2002, 79:29-40.
209. Huang Z., Zhang Z., Jiang Y., Zhang D., Chen J., Dong L., et al. Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy. J Control Release 2012, 158:286-292.
210. Etzerodt A., Maniecki M.B., Graversen J.H., Møller H.J., Torchilin V.P., Moestrup S.K. Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release 2012, 160:72-80.
211. Altunbas A., Lee S.J., Rajasekaran S.A., Schneider J.P., Pochan D.J. Encapsulation of curcumin in self-assembling peptide hydrogels as injectable drug delivery vehicles. Biomaterials 2011, 32:5906-5914.
212. Shpaisman N., Sheihet L., Bushman J., Winters J., Kohn J. One-step synthesis of biodegradable curcumin-derived hydrogels as potential soft tissue fillers after breast cancer surgery. Biomacromolecules 2012, 13:2279-2286.